NEW YORK — Johnson & Johnson (NYSE: JNJ) is a compelling buy for conservative, long-term investors in 2026, with analysts maintaining a consensus "Moderate Buy" rating as the healthcare giant delivers steady earnings growth, robust cash flow and one of the longest dividend increase streaks in corporate America. Despite a slower-growth profile than pure biotech names, JNJ's diversified portfolio, pricing power and defensive qualities make it attractive amid economic uncertainty and market volatility.

Shares have traded in the $148–$155 range in early May, offering a reliable 3.1% dividend yield and 63 consecutive years of dividend increases. The average 12-month price target from analysts sits near $168–$172, implying roughly 10–15% upside. Of roughly 25 analysts covering the stock, the majority rate it Buy or Hold, citing its resilience and capital return discipline.

Johnson & Johnson reported solid first-quarter 2026 results, with adjusted earnings per share of $2.71 beating consensus estimates of $2.58. Revenue reached $22.1 billion, up 6.2% on an operational basis. The Innovative Medicine (pharmaceuticals) segment grew 8.1%, fueled by strong performance from Darzalex, Tremfya, Erleada and other key oncology and immunology products. MedTech sales rose 5.3%, supported by surgical, orthopedics and vision care........

© International Business Times